Arcadia Biosciences, Inc 8-K, filed Feb 22, 2023
Arcadia Biosciences, Inc. (RKDA)
About this 8-K
Arcadia Biosciences, Inc filed this 8-K on February 22, 2023, reporting on events of February 15, 2023.
Items reported
- Item 5.07: Shareholder vote results
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On February 15, 2023, Arcadia Biosciences, Inc. (“Company”) held a special meeting of stockholders (“Special Meeting”). At the Special Meeting, the proposals described below were submitted to a vote of the holders of the Company’s Common Stock and Series A Preferred Stock, voting together as a single class. As of the close of business on December 30, 2022, the record date for the Special Meeting, there were 24,642,960 shares of Common Stock and 24,642.96 shares of shares of Series A Preferred Stock outstanding and entitled to vote on the proposals described below. Each proposal is described in detail in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on January 6, 2023.
The Company’s stockholders approved each of the proposals set forth below at the Special Meeting. The final voting results are as follows:
|
|
|
|
|
|
|
FOR |
|
AGAINST |
|
ABSTAIN |
|
Broker Non-Votes |
9,730,160,440 |
|
1,678,239,563 |
|
229,293,064 |
|
-- |
|
|
|
|
|
|
|
FOR |
|
AGAINST |
|
ABSTAIN |
|
Broker Non-Votes |
9,995,797,812 |
|
1,260,616,357 |
|
381,278,898 |
|
-- |
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
|
|
Exhibit No. |
|
Description |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
ARCADIA BIOSCIENCES, INC. |
|
|
|
|
Date: |
February 21, 2023 |
By: |
/s/ Thomas J. Schaefer |
|
|
|
Thomas J. Schaefer, Chief Financial Officer |